The Long Comedown

At 3 a.m. in a converted tram depot on the edge of the city, the music has slowed to a heartbeat and nobody is dancing so much as swaying inside their own weather. The drug going around tonight isn't new, exactly - it was synthesised in a lab in 1962 and has spent sixty years as an anaesthetic, a horse tranquiliser, a punchline. But the version moving through this room has been rebranded, microdosed, and folded into a wellness vocabulary its inventors would not recognise.

What changed was not the molecule. What changed was the story we tell about it.

For most of the last decade, the conversation about dissociatives lived in two places: the emergency room and the meme. Then the clinics arrived - bright, expensive, lined with succulents - offering the same compound as a treatment for the kind of sadness that doesn't respond to anything else. The clinics were careful. The culture was not. Somewhere between the prescription pad and the cloakroom, the dose got bigger and the supervision disappeared.

"People think because a doctor can give it to you, it must be gentle," a harm-reduction worker tells me, restocking a table of test strips and electrolyte sachets near the fire exit. "It is the opposite of gentle. It just doesn't look dramatic from the outside."

The comedown is the part nobody posts. It arrives a day late, quietly, like a bill. People describe a flatness - not depression exactly, but a sense that the volume on the world has been turned down a notch and left there. They take a little more the next weekend to find the knob.

None of this is an argument for panic. Panic is what gave us the last forty years of drug policy, and the room I'm standing in is the result: smart, curious people self-medicating in the dark because the daylight options ran out. The question worth asking isn't whether the kids are alright. It's why the only institutions that took their pain seriously were a nightclub and a start-up.